High-affinity T cell receptor ImmTAC® bispecific efficiently redirects T cells to kill tumor cells expressing the cancer-testis antigen PRAME.
Ribeiro AR, Britton-Rivet C, Collins L, Carreira RJ, Moureau S, Benlahrech A, Stanhope S, Harper S, Liddy N, Mahon TM, Petrovic K, Fife M, Depoil D, Addis P, Bedke N, Bouard L, O'Dwyer R, Gascoyne D, Ranade K.
Ribeiro AR, et al. Among authors: collins l.
Immunother Adv. 2024 Nov 2;4(1):ltae008. doi: 10.1093/immadv/ltae008. eCollection 2024.
Immunother Adv. 2024.
PMID: 39659431
Free PMC article.